1 Global Pain Management Devices Market Insight Analysis
The global pain management devices market will be valued at USD 7,443.72 million in 2025, with a CAGR of 7.42% from 2025 to 2033.
Pain is an unpleasant feeling and emotional experience caused by tissue damage or disease. It is caused by injuries and various diseases such as osteoarthritis, chronic arthritis, diabetes, multiple sclerosis and cancer. Pain can be divided into acute pain and chronic pain. Pain can be treated with a set of specific drugs or devices. Pain management equipment can be used to reduce pain and improve the quality of life.
Figure Global Pain Management Devices Market Size (M USD) and CAGR (2025-2033)
2 Pain Management Devices Market Growth Drivers and Restraints
Chronic diseases and the increase in the aging population
The global aging trend is intensifying, and the proportion of people over 65 years old continues to rise (such as 28.7% in Japan). With the increase in the prevalence of chronic diseases (such as diabetes, arthritis, and cancer), there is a demand for long-term pain management devices. For example, the demand for implantable devices (such as spinal cord stimulators SCS and infusion pumps) for patients with neuropathic pain and cancer pain has increased significantly, driving market expansion.
Technological innovation and product upgrades
Industry technology iteration is accelerating. For example, wireless remote control and rechargeable devices (such as Medtronic’s Intellis spinal cord stimulation system) improve patient convenience, and the accuracy and safety of radiofrequency ablation (RF Ablation) and transcutaneous electrical nerve stimulation (TENS) devices are continuously optimized. In addition, smart interconnection technology (such as Bluetooth-connected analgesic pumps) combined with medical informatization promote remote monitoring and personalized treatment, enhancing market attractiveness.
Support for medical policies and payment systems
Policies in various countries tend to favor non-drug pain management to reduce opioid abuse. For example, the US FDA has accelerated the approval of new neuromodulatory devices (such as Abbott’s Proclaim XR system), and China’s “tiered diagnosis and treatment” policy has promoted primary medical care to purchase cost-effective domestic equipment. The coverage of medical insurance in some countries has been expanded to improve patients’ ability to pay.
Emerging market demand explosion
The Asia-Pacific region (especially China and India) has become the fastest growing market due to economic growth, improved medical infrastructure and increased health awareness. In 2020, the Asia-Pacific market revenue accounted for 19.62%, and it is expected to continue to expand at a compound annual growth rate of 8.86% in 2026, surpassing mature markets in Europe and the United States.
Post-epidemic recovery and preference for non-surgical treatment
Although the initial COVID-19 caused elective surgery to be delayed, the demand for non-invasive pain management rebounded after the epidemic. Patients prefer to avoid the risk of hospital infection and choose home devices (such as TENS), driving the growth of consumer product sales.
Substitute competition and drug dependence
Non-steroidal anti-inflammatory drugs (NSAIDs) and opioids are still the first choice for short-term pain. They are cheap and easy to obtain, especially in developing countries, squeezing the market space for equipment. Some patients are resistant to invasive devices (such as implantable SCS) and prefer conservative treatment.
High cost and insufficient medical insurance coverage
High-end equipment (such as spinal cord stimulators) are expensive (more than $10,000 per unit) and are not included in medical insurance in some countries, limiting their popularity. For example, due to limited payment capacity, the South American and African markets mainly rely on basic equipment (such as TENS), and the penetration rate of high-end products is low.
Technical barriers and fierce market competition
The market is highly concentrated in leading companies such as Medtronic and Abbott (North American companies account for more than 50% of the global share), and new entrants face patent barriers and channel monopoly. For example, Medtronic’s SCS system accounts for more than 55% of the global market share, and it is difficult for small and medium-sized enterprises to break through the technological moat.
Epidemic and supply chain risks
COVID-19 has caused global supply chain disruptions, and chip shortages and logistics delays have pushed up manufacturing costs. At the same time, hospitals prioritized responding to the epidemic, and the number of non-emergency pain management surgeries decreased. The global market size in 2020 fell slightly by 0.2% year-on-year, and some small and medium-sized enterprises faced bankruptcy pressure.
Strict regulations and long clinical validation cycles
Medical devices must pass strict certification such as FDA and CE, and clinical trials take a long time (e.g., the average R&D cycle for neuromodulation devices is 5-7 years), which slows down the launch of new products. The regulatory system in emerging markets (such as Southeast Asia) is imperfect, which affects the promotion of equipment standardization.
3 Technological Innovations in the Pain Management Devices Market
Innovation in neuromodulation technology
Spinal cord stimulation (SCS): Upgrading from traditional electrical stimulation to high frequency (such as Nevro’s HF10 therapy) and paraesthesia-free stimulation to reduce patient discomfort and improve analgesia. Medtronic’s RestoreSensor system optimizes treatment plans through real-time physiological monitoring.
Radiofrequency ablation (RF): Cooling radiofrequency technology (such as Avanos’ Coolief system) expands the ablation range and reduces the risk of nerve damage, which is suitable for complex pain (such as lumbar postoperative syndrome).
Intelligent and wearable devices
Wearable TENS devices integrate APP to achieve automatic dose adjustment and data cloud synchronization (such as Omron’s HBP-1100).
Implantable devices combined with AI predict pain attacks and intervene in advance through machine learning (such as Boston Scientific’s Precision Montage system).
Biodegradable materials and minimally invasive technology
New materials (such as polylactic acid stents) are used for absorbable nerve stimulation electrodes to avoid long-term implant risks. Minimally invasive surgical instruments (such as Stryker’s MultiGen 2 radiofrequency generator) simplify the operation process and shorten the operation time to less than 30 minutes.
Telemedicine and personalized treatment
Bluetooth-connected devices (such as Abbott’s Proclaim XR) support doctors’ remote programming, and patients can provide real-time feedback of pain data through mobile phones, promoting the popularization of the “home pain management” model. Genetic testing guides equipment selection (such as optimizing SCS parameters based on COMT gene polymorphism).
Horizontal expansion of leading companies
Medtronic: Through the acquisition of Covidien, it expanded its minimally invasive product line and integrated neuromodulation and pain management businesses. In 2020, the pain management department’s revenue reached US$13.17 billion, accounting for 25.6% of the global market.
Abbott: After acquiring St. Jude Medical, combined with its neuromodulation technology, it launched a battery-free SCS system with a battery life of 10 years, seizing the high-end market.
Regional market integration
Asia-Pacific layout: Johnson & Johnson acquired Pymetrics, an Indian local company, to strengthen grassroots market channels; Mindray Medical entered the field of anesthesia and pain equipment through the acquisition of Shenzhen Pubo, and the market share of domestic TENS equipment exceeded 30%.
Emerging market acquisitions: Stryker acquired Brazil’s Neurotech to consolidate the South American market. In 2020, South American revenue accounted for 12.9% of its pain management business.
Technology startup mergers and acquisitions
Boston Scientific acquired Nevro’s competitor Spinal Modulation to obtain high-frequency stimulation patented technology to suppress potential threats.
Private equity funds invested in home pain equipment startups (such as NuroKor in the UK) to promote the commercialization of non-invasive equipment. In 2021, the global home pain equipment market size reached US$2.3 billion, a year-on-year increase of 15%.
4 Global Pain Management Devices Market Size by Type
SCS devices are anticipated to dominate the market in 2025, with an estimated market size of $4,287.59 million USD. This represents a substantial market share of 57.60%, highlighting the preference and effectiveness of SCS devices in managing chronic pain conditions. SCS devices work by sending electrical impulses to the spinal cord to disrupt pain signals before they reach the brain, offering a non-pharmacological approach to pain management.
TENS devices, though holding a smaller market share of 2.49%, are expected to generate a revenue of $185.29 million USD in 2025. TENS devices are used to stimulate peripheral nerves via the skin, thereby reducing pain perception. Despite their smaller market share, TENS devices are crucial for patients seeking non-invasive pain management options.
RF Ablation devices are projected to have a market size of $1,861.28 million USD in 2025, capturing a market share of 25.00%. These devices use radiofrequency energy to heat and ablate nerves, thereby reducing pain transmission. RF Ablation is often used for treating chronic joint pain and other neuropathic conditions, offering a precise and targeted treatment approach.
Infusion Pumps, while having the smallest market share among the four types at 14.91%, are expected to contribute a revenue of $1,109.56 million USD in 2025. These devices deliver medications directly to the site of pain, providing a controlled and continuous pain relief. Infusion pumps are particularly useful for managing chronic pain conditions that require ongoing medication.
Table Global Pain Management Devices Market Size and Share by Type in 2025
Type | Market Size (M USD) 2025 | Market Share 2025 |
|---|---|---|
SCS | 4287.59 | 57.60% |
TENS | 185.29 | 2.49% |
RF Ablation | 1861.28 | 25.00% |
Infusion Pumps | 1109.56 | 14.91% |
5 Global Pain Management Devices Market Size by Application
In 2025, the market revenue for pain management devices used for neuropathic pain is projected to reach 4191.14 million USD, accounting for 56.30% of the total market share. Neuropathic pain is caused by damage or disease affecting the somatosensory nervous system. This type of pain is often chronic and can be difficult to manage. Devices such as spinal cord stimulators, nerve stimulators, and certain types of drug – delivery systems are commonly used to alleviate neuropathic pain.
The high revenue and market share are indicative of the large patient population suffering from neuropathic pain conditions like diabetic neuropathy, post – herpetic neuralgia, and trigeminal neuralgia. The continuous innovation in devices for neuropathic pain management, such as the development of more precise and less invasive stimulation technologies, also contributes to its significant market presence.
The market revenue for cancer pain management devices in 2025 is expected to be 841.89 million USD, with a market share of 11.31%. Cancer pain is a common and often severe symptom experienced by cancer patients at various stages of their illness. Pain management devices for cancer pain include infusion pumps for delivering analgesic drugs, and some advanced neuromodulation devices.
The relatively high revenue is due to the increasing incidence of cancer globally and the growing recognition of the importance of effective pain management in improving the quality of life of cancer patients. However, the market share is relatively smaller compared to neuropathic pain mainly because the patient population is more specific to cancer patients, while neuropathic pain can affect a wider range of individuals.
For facial pain and migraine, the projected market revenue in 2025 is 536.73 million USD, holding a market share of 7.21%. Migraine is a common neurological disorder characterized by severe headaches, often accompanied by other symptoms such as nausea, sensitivity to light and sound. Facial pain can result from various conditions like trigeminal neuralgia. Devices such as transcutaneous electrical nerve stimulation (TENS) units, which deliver mild electrical impulses to the nerves, are used to manage these types of pain. The market for these devices is growing as more people seek non – pharmacological options for pain relief, and as awareness about the effectiveness of these devices increases.
The market revenue for musculoskeletal pain management devices is projected to be 1062.07 million USD in 2025, with a market share of 14.27%. Musculoskeletal pain is widespread, affecting muscles, bones, joints, ligaments, and tendons. Conditions such as arthritis, back pain, and sports – related injuries fall into this category. Devices like orthopedic braces, massage devices, and some types of electrotherapy devices are used for management. The relatively high revenue and market share are due to the large number of people affected by musculoskeletal conditions, which can be caused by factors such as aging, sedentary lifestyles, and physical injuries.
Table Global Pain Management Devices Market Size and Share by Application in 2025
Application | Market Size (M USD) 2025 | Market Share 2025 |
|---|---|---|
Neuropathic Pain | 4191.14 | 56.30% |
Cancer Pain | 841.89 | 11.31% |
Facial Pain and Migraine | 536.73 | 7.21% |
Musculoskeletal Pain | 1062.07 | 14.27% |
Others | 811.90 | 10.91% |
6 Global Pain Management Devices Market Size by Region
In 2025, North America is expected to have a market revenue of 3892.26 million USD. North America has a well – developed healthcare infrastructure, high healthcare spending, and a large patient pool suffering from chronic pain conditions. The region is home to many leading medical device manufacturers and innovators, which gives it a competitive edge. Advanced technologies such as spinal cord stimulation (SCS) and other sophisticated pain management devices are widely adopted here. The high cost – effectiveness of these devices in managing long – term pain has also contributed to the substantial market revenue.
Europe is projected to generate a market revenue of 1616.47 million USD in 2025. The European market benefits from a high level of healthcare awareness among its population. Stringent regulatory frameworks ensure the quality and safety of pain management devices, which in turn boosts consumer confidence. Additionally, the increasing prevalence of musculoskeletal disorders and neuropathic pain has driven the demand for pain management solutions. European countries also invest in research and development, leading to the continuous improvement of existing devices and the introduction of new ones.
The Asia Pacific region is expected to have a market revenue of 1585.83 million USD in 2025. This region has been experiencing rapid growth in the pain management devices market. Factors such as a growing population, rising disposable income, and improving healthcare facilities are fueling the demand. China and India, in particular, are emerging as significant markets. The increasing adoption of minimally invasive pain management techniques and the growing preference for home – based pain management solutions are also contributing to the market expansion. Moreover, local manufacturers are becoming more competitive, offering cost – effective alternatives to imported devices.
South America is projected to have a market revenue of 193.23 million USD in 2025. Although the market size is relatively smaller compared to the aforementioned regions, it has growth potential. The region is gradually improving its healthcare infrastructure, and there is an increasing awareness of advanced pain management solutions. However, challenges such as limited healthcare budgets in some countries and a lack of widespread access to high – end devices still exist. Nevertheless, as economic conditions improve and healthcare spending increases, the market is expected to grow further.
In 2025, the Middle East and Africa region is expected to generate a market revenue of 155.94 million USD. This region faces a mix of opportunities and challenges. The presence of a large population with a high burden of chronic diseases such as cancer and arthritis creates a demand for pain management devices. However, issues like a lack of advanced healthcare facilities in some areas, limited reimbursement policies, and a shortage of skilled medical professionals can impede market growth. Despite these challenges, the region is gradually making progress in improving healthcare services, which will likely drive the growth of the pain management devices market in the future.
Figure Global Pain Management Devices Market Size (M USD) by Region in 2025
7 Global Pain Management Devices Market Analysis by Major Players
Medtronic plc
Company Profile: Established in 1949 and headquartered in Ireland, Medtronic plc is a global leader in medical technology, services, and solutions. The company is renowned for its broad range of offerings that cater to various healthcare needs, from cardiovascular to neurological conditions.
Business Overview: Medtronic operates worldwide, focusing on developing, manufacturing, and marketing medical devices. Their products are designed to alleviate pain, manage chronic diseases, and improve the overall quality of patient care. The company’s commitment to innovation and excellence has made it a trusted name in the healthcare industry, with a strong presence in over 150 countries.
Product Offered: In the pain management devices segment, Medtronic offers a range of solutions including spinal cord stimulation (SCS) systems, implantable drug infusion systems for chronic pain, and interventional products. Their flagship products include the Intellis Spinal Cord Stimulation System, which features AdaptiveStim technology and SureScan MRI compatibility, allowing for a more personalized and flexible treatment approach. Additionally, Medtronic provides interventional products like the Xpander II Balloon Kyphoplasty system and the OsteoCool RF Tumor ablation system, enhancing their position as a comprehensive pain management solutions provider.
Abbott Laboratories
Company Profile: Founded in 1888 and headquartered in the USA, Abbott Laboratories is a diversified healthcare company committed to improving lives through the development of medical products, including devices, diagnostics, nutritionals, and pharmaceuticals.
Business Overview: Abbott operates globally, with a focus on delivering innovative healthcare solutions that address various medical conditions. The company’s broad portfolio includes products for cardiovascular health, diabetes care, neurological disorders, and pain management, among others. Abbott’s commitment to research and development has helped it maintain a leading position in the healthcare sector.
Product Offered: In the pain management devices market, Abbott offers advanced solutions such as the NT2000iX™ Radiofrequency Generator for chronic pain management and the Proclaim™ Elite Recharge-Free SCS System. These products are designed to provide effective pain relief through spinal cord stimulation and radiofrequency ablation, respectively. Abbott’s focus on creating user-friendly and technologically advanced devices positions it as a key player in offering cutting-edge pain management solutions.
Boston Scientific Corporation
Company Profile: Established in 1979 and headquartered in the USA, Boston Scientific Corporation is a leading innovator in the development and manufacturing of medical devices. The company is dedicated to improving patient outcomes through minimally invasive procedures.
Business Overview: Boston Scientific serves a global market, focusing on interventional cardiology, cardiac rhythm management, and neuromodulation, among other areas. The company is known for its commitment to quality, innovation, and customer satisfaction, which has helped it establish a strong reputation in the medical technology sector.
Product Offered: In the pain management devices segment, Boston Scientific offers products like the G4™ RF Generator for radiofrequency ablation and the Precision Montage™ MRI Spinal Cord Stimulator System. These products are designed to provide effective pain relief through advanced stimulation and ablation technologies. The company’s focus on minimally invasive solutions aligns with the growing demand for less intrusive medical procedures, making its products highly relevant in the pain management market.